Upregulation of Fas in epithelial ovarian cancer reverses the development of resistance to cisplatin.

Yang, Fan; Long, Wang; Xuechuan, Han; Xueqin, Liu; Hongyun, Ma; Yonghui, Ding

Yang, Fan; Long, Wang; Xuechuan, Han; Xueqin, Liu; Hongyun, Ma; Yonghui, Ding.

Afiliación

Yang F; Department of Obstetrics and Gynecology, Ningxia People's Hospital, Yinchuan 750002, People's Republic of China.
Long W; Ningxia Medical University, Yinchuan 750004, People's Republic of China.
Xuechuan H; Department of Obstetrics and Gynecology, Ningxia People's Hospital, Yinchuan 750002, People's Republic of China.
Xueqin L; Department of Obstetrics and Gynecology, Ningxia People's Hospital, Yinchuan 750002, People's Republic of China.
Hongyun M; Department of Obstetrics and Gynecology, Ningxia People's Hospital, Yinchuan 750002, People's Republic of China.
Yonghui D; Affiliated Hospital of Ningxia Medical University, Yinchuan 750004, People's Republic of China.

BMB Rep ; 48(1): 30-5, 2015 Jan.

Article en En | MEDLINE | ID: mdl-24755555

RESUMEN

This study was to investigate the role of Fas in the development of Cisplatin-resistant ovarian cancer. On the cellular level, Fas expression was significantly reduced in Cisplatin resistant A2780 (A2780/CP) cells compared with A2780 cells. Fas silence with siRNA would promote tumor cell lines proliferation, facilitate tumor cell cycle transition of G1/S, prevent cell apoptosis, and promote cell migration. Expression of drug resistance gene was negatively correlated to Fas. In nude mice metastasis model of human ovarian carcinoma by subcutaneous transplantation, after Ad-Fas injected intratumorly, we found that upregulation of Fas could inhibit transplantation tumor tissue growth and reduce the expression of drug resistance gene. Our results indicated that upregulation of Fas in epithelial ovarian cancer reversed the development of resistance to Cisplatin. In conclusion, our findings suggested that Fas might act as a promising therapeutic target for improvement of the sensibility to Cisplatin in ovarian cancer.

Asunto(s)

Antineoplásicos/farmacología; Cisplatino/farmacología; Receptor fas/metabolismo; Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo; Animales; Antineoplásicos/uso terapéutico; Apoptosis/efectos de los fármacos; Línea Celular Tumoral; Movimiento Celular/efectos de los fármacos; Cisplatino/uso terapéutico; Resistencia a Antineoplásicos; Femenino; Puntos de Control de la Fase G1 del Ciclo Celular/efectos de los fármacos; Humanos; Ratones; Ratones Desnudos; Proteína 2 Asociada a Resistencia a Múltiples Medicamentos; Proteínas Asociadas a Resistencia a Múltiples Medicamentos/metabolismo; Neoplasias Ováricas/tratamiento farmacológico; Neoplasias Ováricas/metabolismo; Neoplasias Ováricas/patología; Interferencia de ARN; ARN Interferente Pequeño/metabolismo; Trasplante Heterólogo; Regulación hacia Arriba; Partículas Ribonucleoproteicas en Bóveda/metabolismo; Receptor fas/antagonistas & inhibidores; Receptor fas/genética

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cisplatino / Receptor fas / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: BMB Rep Asunto de la revista: BIOLOGIA MOLECULAR / BIOQUIMICA Año: 2015 Tipo del documento: Article Pais de publicación: Corea del Sur

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google